A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Part 1 (Phase 1a): The purpose of this study is to test the safety of a study drug , NGM120, in participants with advanced pancreatic, colorectal, esophageal, and gastric cancer.
Part 2 (Phase 1b): The purpose of this study is to test the safety of a study drug, NGM120, combined with standard therapy, gemcitabine and nab-paclitaxel in participants with advanced pancreatic cancer.
-Males and females 18 years or older
-Have a life expectancy of at least 12 weeks
-Part 1 only: Histologically confirmed advanced or metastatic colorectal, pancreatic, gastric, or esophageal cancer
-Part 2 only: Histologically confirmed advanced or metastatic pancreatic
-Use of immunosuppressive medications within 14 days screening
-Active infections or other serious underlying significant medical illness
18 - 100
Healthy Volunteers Needed
Duration of Participation
Up to 23 months
Knight Clinical Trials Information Line
NGM Biopharmaceuticals, Inc.
Participants will be given a Fitbit device as part of the study. Participants will be given the option to keep the Fitbit if a before study procedures and at least 1 follow-up visit are completed.